Prevention and Treatment of C. difficile Infection

Rationale for Metronidazole Use

The Infectious Diseases Society of America recommends metronidazole for anaerobic coverage in treating intra-abdominal infections, but not specifically for C. difficile prevention 3, 4
The combination of cefepime and metronidazole is recommended for treating intra-abdominal infections to ensure coverage against both aerobic and anaerobic pathogens, as suggested by the World Journal of Emergency Surgery 4

The primary strategy for preventing C. difficile infection is discontinuing the inciting antibiotic agent(s) as soon as possible, according to the Clinical Infectious Diseases guidelines 2, 5
There is no recommendation in current guidelines to add metronidazole to any antibiotic regimen specifically to prevent C. difficile infection, as stated by the Infectious Diseases Society of America 1, 2
The IDSA/SHEA guidelines no longer recommend metronidazole as first-line therapy even for treatment of non-severe C. difficile infection 1, 6

Current guidelines recommend either vancomycin or fidaxomicin over metronidazole for initial episodes of C. difficile infection, as suggested by the Clinical Infectious Diseases guidelines 1, 2, 6
Metronidazole is now only suggested for initial episodes of non-severe CDI in settings where access to vancomycin or fidaxomicin is limited, according to the World Journal of Emergency Surgery 2, 7
Prolonged or repeated courses of metronidazole should be avoided due to risk of cumulative and potentially irreversible neurotoxicity, as warned by the Clinical Infectious Diseases guidelines 2, 7

There is no evidence supporting the use of metronidazole as prophylaxis against C. difficile infection when administering cefepime, as stated by the Clinical Infectious Diseases guidelines 5

The most effective strategy for preventing C. difficile infection remains judicious use of antibiotics and discontinuing them as soon as possible, according to the Clinical Infectious Diseases guidelines 2, 5
If C. difficile infection does develop, current guidelines recommend vancomycin or fidaxomicin as first-line therapy in most cases, as suggested by the IDSA/SHEA guidelines 1, 6, 7